Oral Dosage Form New Animal Drugs; Milbemycin Oxime Tablet

Resumen

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The supplemental NADA provides for expanding the indications to include separate dosage and labeling for use of milbemycin oxime in cats.